|
QRSL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62647673107585E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.00950367457153E-14 |
| Normal-vs-Stage2 |
1.880100E-03 |
| Normal-vs-Stage3 |
1.33226762955019E-15 |
| Normal-vs-Stage4 |
2.02504679691629E-12 |
| Stage1-vs-Stage2 |
6.495900E-02 |
| Stage1-vs-Stage3 |
5.804400E-02 |
| Stage1-vs-Stage4 |
5.041500E-02 |
| Stage2-vs-Stage3 |
7.380100E-03 |
| Stage2-vs-Stage4 |
4.824600E-03 |
| Stage3-vs-Stage4 |
6.236200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.41379999998959E-06 |
| Normal-vs-Asian |
2.65089999951229E-07 |
| Caucasian-vs-AfricanAmerican |
1.806390E-01 |
| Caucasian-vs-Asian |
4.923500E-02 |
| AfricanAmerican-vs-Asian |
8.916200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.77395900588817E-15 |
| Normal-vs-Female |
1.76103576166042E-12 |
| Male-vs-Female |
3.072400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.67676983409137E-12 |
| Normal-vs-Age(41-60Yrs) |
8.63753513158372E-14 |
| Normal-vs-Age(61-80Yrs) |
4.47299997041739E-09 |
| Normal-vs-Age(81-100Yrs) |
6.05750000000072E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.110200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.266600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.444600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.651380E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.155800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.617600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.583450E-01 |
| Classical-VS-Follicular |
3.95960000000306E-05 |
| Classical-VS-Other |
2.272000E-01 |
| Classical-VS-Normal |
1.6242562850266E-12 |
| Tall-VS-Follicular |
1.53706000000087E-05 |
| Tall-VS-Other |
5.761600E-01 |
| Tall-VS-Normal |
8.4900975139135E-12 |
| Follicular-VS-Other |
1.521890E-03 |
| Follicular-VS-Normal |
1.339620E-03 |
| Other-VS-Normal |
1.56235999999588E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.50539597349098E-11 |
| Normal-vs-N1 |
5.72031311207866E-12 |
| N0-vs-N1 |
4.198300E-02 |
|
|
